IMCR

Immunocore Holdings plc (NASDAQ:IMCR) is a commercial-stage biotechnology company founded in 1999 and headquartered in Abingdon, United Kingdom. The company went public in February 2021 and has established itself as a pioneer in developing a novel class of immunotherapies called ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) therapeutics. Immunocore's lead product, <b>KIMMTRAK</b>, became the first FDA-approved treatment for unresectable or metastatic uveal melanoma, a rare and deadly form of eye cancer. The company has evolved from a research-focused organization into a commercial enterprise with global operations, having launched KIMMTRAK in 24 countries and treating over 2,000 patients worldwide.